Avadel Pharmaceuticals (AVDL) Competitors $18.56 +0.04 (+0.22%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$18.55 -0.01 (-0.05%) As of 10/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVDL vs. PTGX, TGTX, PTCT, KRYS, ARWR, ACLX, AKRO, CRNX, MENS, and NAMSShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Its Competitors Protagonist Therapeutics TG Therapeutics PTC Therapeutics Krystal Biotech Arrowhead Pharmaceuticals Arcellx Akero Therapeutics Crinetics Pharmaceuticals Jyong Biotech NewAmsterdam Pharma Avadel Pharmaceuticals (NASDAQ:AVDL) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings. Do analysts rate AVDL or PTGX? Avadel Pharmaceuticals currently has a consensus price target of $18.72, suggesting a potential upside of 0.87%. Protagonist Therapeutics has a consensus price target of $74.00, suggesting a potential upside of 0.01%. Given Avadel Pharmaceuticals' higher probable upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.42Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media prefer AVDL or PTGX? In the previous week, Avadel Pharmaceuticals had 24 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 29 mentions for Avadel Pharmaceuticals and 5 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.16 beat Avadel Pharmaceuticals' score of 0.01 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in AVDL or PTGX? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, AVDL or PTGX? Avadel Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Which has better earnings & valuation, AVDL or PTGX? Protagonist Therapeutics has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$169.12M10.66-$48.83M-$0.03-618.67Protagonist Therapeutics$434.43M10.60$275.19M$0.70105.70 Is AVDL or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Avadel Pharmaceuticals' net margin of -1.32%. Protagonist Therapeutics' return on equity of 8.12% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% Protagonist Therapeutics 24.88%8.12%7.41% SummaryProtagonist Therapeutics beats Avadel Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$2.64B$6.18B$10.59BDividend YieldN/A57.75%5.72%4.86%P/E Ratio-618.6723.9429.6728.46Price / Sales10.66778.82579.41225.02Price / CashN/A165.1936.5560.64Price / Book24.105.5712.076.53Net Income-$48.83M$33.06M$3.32B$276.75M7 Day Performance21.94%2.10%0.64%0.93%1 Month Performance19.05%5.91%5.17%1.41%1 Year Performance42.77%-2.82%61.77%31.59% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals1.345 of 5 stars$18.56+0.2%$18.72+0.9%+40.4%$1.80B$169.12M-618.6770Trending NewsAnalyst DowngradeOptions VolumeHigh Trading VolumePTGXProtagonist Therapeutics1.6135 of 5 stars$79.17-9.0%$72.00-9.1%+58.8%$5.41B$434.43M113.10120Positive NewsHigh Trading VolumeTGTXTG Therapeutics4.3332 of 5 stars$34.22+1.4%$49.00+43.2%+44.8%$5.36B$329M92.49290News CoveragePositive NewsPTCTPTC Therapeutics3.2734 of 5 stars$66.06-0.3%$69.00+4.5%+57.3%$5.26B$806.78M9.481,410KRYSKrystal Biotech4.8285 of 5 stars$184.74+1.8%$209.00+13.1%+7.9%$5.25B$290.52M37.55210ARWRArrowhead Pharmaceuticals3.7824 of 5 stars$36.25+2.4%$43.14+19.0%+87.5%$4.90B$3.55M-28.32400Positive NewsACLXArcellx2.4802 of 5 stars$86.23-0.7%$112.69+30.7%-4.7%$4.81B$107.94M0.0080AKROAkero Therapeutics3.84 of 5 stars$53.66-0.4%$73.38+36.7%+87.4%$4.31BN/A-26.8330Positive NewsCRNXCrinetics Pharmaceuticals4.2826 of 5 stars$44.43-1.1%$74.45+67.6%-31.4%$4.23B$1.04M-10.81210MENSJyong BiotechN/A$55.70+0.8%N/AN/A$4.20BN/A0.0031NAMSNewAmsterdam Pharma3.4189 of 5 stars$37.15+0.3%$42.00+13.1%+88.0%$4.17B$45.56M-22.934Trending NewsAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies PTGX Competitors TGTX Competitors PTCT Competitors KRYS Competitors ARWR Competitors ACLX Competitors AKRO Competitors CRNX Competitors MENS Competitors NAMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVDL) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredGold surges past $4,200 … but this has beat gold by 1,000xGold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVDL Stock Alerts